- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00598572
Dose Finding and Safety Study of Deferoxamine in Patients With Brain Hemorrhage (DFO In ICH)
Safety and Tolerability of Deferoxamine in Acute Cerebral Hemorrhage
Animal studies show that the breakdown of blood results in iron accumulation in the brain after brain hemorrhage (ICH); and that iron plays a role in brain injury in ICH patients. Deferoxamine (DFO) has been extensively used in clinical practice for more than 30 years to remove excessive iron from the body, and has been shown to provide some benefit in animal studies of ICH. Therefore, we plan to undertake this study to evaluate the safety and tolerability of treatment with DFO in patients with ICH, and to determine the maximal tolerated dose to be used in future studies to determine if treatment with DFO can improve the outcome of patients with ICH.
Our main objectives are: 1) to evaluate the safety and tolerability of varying doses of DFO, by determining the treatment related adverse events, in patients with ICH; and 2) to determine the maximal tolerated dose to be adopted in subsequent studies to test the efficacy of DFO in improving outcome after ICH.
We hypothesize that DFO is well-tolerated and has minimal serious adverse effects in patients with ICH; and that treatment with DFO will improve patients' outcome. The results can potentially bring into account new means to improve the outcome of patients with ICH. ICH is a frequent cause of disability and death. A successful study demonstrating the efficacy of iron-modifying therapy would be of considerable public health significance.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- Beth Israel Deaconess Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age ≥ 18 years
- The diagnosis of ICH is confirmed by brain CT scan.
- The first dose of the study drug can be administered within 18 hours of ICH symptom onset.
- Signed and dated informed consent is obtained
- Stable clinical and neurological status. Patients whose clinical or neurological status significantly deteriorates compared to presentation prior to administration of the study drug will be excluded.
Exclusion Criteria:
- Previous chelation therapy or known hypersensitivity to DFO products
- Abnormal renal function (serum creatinine > 2 mg/dl)
- Known severe iron deficiency anemia
- Planned surgical evacuation of ICH prior to administration of the study drug
- Patients with suspected secondary ICH related to tumour, coagulopathy, ruptured aneurysm or arteriovenous malformation, or venous sinus thrombosis
- Evidence of significant shift of midline brain structure (> 10 mm) or herniation on imaging studies.
- Deep coma (Glasgow Coma Score (GCS) = 3-5) upon presentation
- Taking iron supplements or prochlorperazine
- Patients with heart failure taking > 500 mg of vitamin C daily
- Known hearing impairment
- Systolic blood pressure < 100 mmHg or diastolic blood pressure < 60 mmHg, confirmed by 3 consecutive readings
- Significant chronic respiratory insufficiency
- Known pregnancy (or positive pregnancy test), or breast-feeding
- Patients known or suspected of not being able to comply with the study protocol due to alcoholism, drug dependency, incompliance, or any other cause.
- Any condition which, in the judgement of the investigator, might increase the risk to the patient
- Life expectancy of less than 90 days due to co-morbid conditions
- Concurrent participation in another research protocol for investigation of another experimental therapy
- Pre-existing Do Not Resuscitate (DNR) order, or indication that a new DNR order will be implemented within the first 48 hours of hospitalization. -
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1
All participants will receive various dose-regimens of the study drug (deferoxamine mesylate).
Each dose cohort will consist of at least 3 subjects.
|
Various dose-regimens ranging from 7 mg/kg to 125 mg/kg (with a maximum allowable total daily dose of 6000 mg at any of the tested dose tiers, regardless of patient's weight), administered daily by IV infusion for three consecutive days.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Dose-limiting toxicities
Time Frame: First 7 days of hospitalization or diacharge, whichever occurs earlier
|
First 7 days of hospitalization or diacharge, whichever occurs earlier
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Magdy Selim, MD, PhD, Beth Israel Deaconess Medical Center
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Cardiovascular Diseases
- Vascular Diseases
- Cerebrovascular Disorders
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Intracranial Hemorrhages
- Hemorrhage
- Cerebral Hemorrhage
- Molecular Mechanisms of Pharmacological Action
- Chelating Agents
- Sequestering Agents
- Iron Chelating Agents
- Siderophores
- Deferoxamine
Other Study ID Numbers
- 2007P000288
- 1R01NS057127-01A1 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Intracerebral Hemorrhage
-
Wake Forest University Health SciencesActive, not recruitingStroke Hemorrhagic | Intracerebral Hemorrhage | Cerebral Edema | Intracerebral Hemorrhage, Hypertensive | Intracerebral Hemorrhage IntraparenchymalUnited States
-
Beijing Tiantan HospitalBeijing Friendship Hospital; RenJi Hospital; Qilu Hospital of Shandong University and other collaboratorsRecruitingSpontaneous Intracerebral HemorrhageChina
-
University Hospital, Basel, SwitzerlandSwiss Heart FoundationActive, not recruitingIntracerebral Hemorrhage (ICH)Switzerland
-
University of Erlangen-Nürnberg Medical SchoolCompleted
-
AegisCN LLCCompletedIntracerebral Hemorrhage (ICH)United States
-
Tongji HospitalUnknown
-
Huazhong University of Science and TechnologyUnknownHypertensive Intracerebral HemorrhageChina
-
Huazhong University of Science and TechnologyUnknownHypertensive Intracerebral HemorrhageChina
-
CellMed AG, a subsidiary of BTG plc.TerminatedIntracerebral Hemorrhage (ICH)Germany
-
Tang-Du HospitalRecruitingIntracerebral Hemorrhage;Circulating ExosomesChina
Clinical Trials on Deferoxamine Mesylate
-
Beth Israel Deaconess Medical CenterMedical University of South Carolina; Johns Hopkins University; Massachusetts... and other collaboratorsCompletedIntracerebral HemorrhageUnited States, Canada
-
Dana-Farber Cancer InstituteBrigham and Women's HospitalTerminatedAcute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Myelodysplastic SyndromeUnited States
-
Brigham and Women's HospitalDr. Jeffrey Thomas Stroke Shield FoundationTerminatedSubarachnoid HemorrhageUnited States
-
Capital Medical UniversityPeking University First Hospital; Peking University People's Hospital; Beijing... and other collaboratorsUnknownIntracerebral HemorrhageChina
-
Beth Israel Deaconess Medical CenterMedical University of South Carolina; Johns Hopkins University; Massachusetts... and other collaboratorsTerminatedIntracerebral HemorrhageUnited States, Canada
-
Novartis PharmaceuticalsCompletedTransfusional Hemosiderosis | Transfusional Iron OverloadTaiwan, Turkey, Egypt, United Kingdom, Thailand, Canada, China, Italy, Cyprus, Lebanon, United Arab Emirates
-
Memorial Sloan Kettering Cancer CenterCenter for Experimental Therapeutics; F.M. KIRBY FOUNDATIONRecruitingLeptomeningeal MetastasesUnited States
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedHematologic Diseases | Iron Overload | Hemoglobinopathies | Thalassemia | Beta-Thalassemia | Hemochromatosis | Anemia (Iron-Loading)
-
Elliott VichinskyCompletedIron Overload | ThalassemiaUnited States
-
TauTona GroupWithdrawnSickle Cell Disease | Chronic Cutaneous UlcerUnited States